泰和诚医疗,concord medical,  
泰和诚是一家专业的医疗服务公司，拥有目前中国最大的肿瘤放射治疗和影像诊断网络。自成立以来，泰和诚一直致力于向中国医疗领域引进国际高科技大型医疗诊断治疗设备，尤其是世界上技术最前沿的肿瘤诊断与放射治疗设备，努力为肿瘤患者提供先进而有效的诊疗手段和优质的医疗服务。时至今日，泰和诚的肿瘤医疗服务网络已经覆盖了中国20多个省市的逾35个主要城市，并继续在更多的地区积极拓展相关的业务。

通过租赁和提供专业管理的方式，泰和诚在中国许多医院都建立了肿瘤诊疗中心。通常每个中心都配备一套先进而昂贵的放射治疗和影像诊断设备，如医用加速器（包括高端的直线加速器和回旋加速器）、头部伽玛刀系统、体部伽玛刀系统、正电子发射计算机断层影像扫描系统或磁共振成像系统。公司向网络各中心的医生提供医疗支持服务，如组织医生会诊和医学研究等。

为进一步增强公司的业务发展，提高公司的声誉，泰和诚投资的两家肿瘤专科医院（包括长安泰和国际肿瘤中心和北京质子中心）正在建设之中，将集中目前国际上最先进的设备与技术，为肿瘤患者提供更加丰富的诊疗手段和更加细分化的服务。

据统计，在2008年，癌症是中国居民死亡的首要病因。而与发达国家相比，中国国内的放射治疗和影像诊断设备的普及率却很低。根据Frost & Sullivan提供的最新数据, 2008年至2015年间，中国放射治疗和影像诊断市场的复合年均增长率预计将达22.4%。增长的主要驱动因素包括中国癌症发病率的不断增长, 医生和患者对癌症的认知度越来越高，以及医院采用先进的放射治疗和影像诊断技术。同时，家庭可支配收入和政府医疗保健支出的不断增长也将进一步提高人们对癌症治疗和诊断费用的支付能力。

泰和诚分布在全国的庞大网络、在肿瘤放射治疗和影像诊断领域的丰富经验，以及业内领先的专家团队使我们能够不断满足中国放射治疗和影像诊断服务市场的迫切需要和不断推动行业的健康发展。

CMS partners with hospitals to build radiotherapy and diagnostic imaging centers. Each center is typically equipped with a primary unit of advanced radiotherapy and diagnostic imaging equipment, such as linear accelerators, head gamma knife systems, body gamma knife systems, positron emission tomography-computed tomography (PET-CT) scanners or magnetic resonance imaging (MRI) scanners. The Company provides clinical support services to doctors working in the centers in its network, such as organizing joint diagnosis among doctors in its network and clinical research, while its hospital partners are responsible for the centers' clinical activities, doctors' medical decisions and the employment of the doctors.

Concord Medical Services Holdings Limited ("CMS" or "the Company") operates China's largest network in terms of revenue and total number of centers in operation in 2008. Since its inception CMS has been committed to building an extensive network of radiotherapy and diagnostic imaging centers in China and employing state-of-the art medical technology to sustain lives and reduce sufferings. Today, the Company operates a network of more than 80 centers spanning more than 35 cities and 20 provinces and administrative regions in China.

To further enhance its reputation and to employ high quality doctors, the Company plans to establish and operate specialty cancer hospitals in China. Its first specialty cancer hospital, the Chang'an CMS International Cancer Center, in Xi'an, Shaanxi Province, is expected to be operational in early 2010. The Company is also in the process of establishing the Beijing Proton Medical Center, which is expected to commence operations in 2012.

Cancer was the leading cause of death in China in 2008, yet there is a relatively low penetration rate of radiotherapy and diagnostic imaging equipment compared to developed countries. According to Frost & Sullivan, the radiotherapy and diagnostic imaging market in China is expected to grow at a CAGR of 22.4% between 2008 and 2015. Growth drivers include increasing cancer rates in China, growing awareness among physicians and patients and hospitals' adoption of advanced radiotherapy and diagnostic imaging technologies. Furthermore, rising household disposable income and government healthcare expenditures will increase the affordability of such cancer treatment and diagnosis technologies.

With its leading network and its experience and expertise, the Company is uniquely positioned to address the underserved radiotherapy and diagnostic imaging services market in China.